Novo Nordisk hopes to begin approval process of once-weekly insulin in H1 2023

Another round of positive study data for insulin icodec has cemented the company’s belief that a global approval process can be initiated at the start of next year, Novo Nordisk executive Martin Holst Lange tells MedWatch.
Martin Holst Lange, executive vice president for Development at Novo Nordisk | Photo: Novo Nordisk / PR
Martin Holst Lange, executive vice president for Development at Novo Nordisk | Photo: Novo Nordisk / PR
by christopher due karlsson, translated by daniel pedersen

If everything pans out for Novo Nordisk in the near future, Denmark’s biggest pharmaceutical company expects to initiate a global application process for once-weekly insulin icodec in the first half of 2023, Executive Vice President for Development at Novo Nordisk Martin Holst Lange tells MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading